MedTrace Logo

A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

NCT02206165 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 456

Last updated 2015-03-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Candesartan/Amlodipine combined or alone and select better dose of CKD-330 in essential hypertension patients.

Conditions

  • Essential Hypertension

Interventions

DRUG

Candesartan 8mg

Once a day, 8 weeks

DRUG

Candesartan 16mg

Once a day, 8 weeks

DRUG

Amlodipine 5mg

Once a day, 8 weeks

DRUG

Amlodipine 10mg

Once a day, 8 weeks

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Cheol-Ho Kim, M.D., Ph.D. · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-04-30
Completion
2015-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02206165 on ClinicalTrials.gov